News
VIRX
0.6252
+9.88%
0.0562
Weekly Report: what happened at VIRX last week (0610-0614)?
Weekly Report · 5d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Viracta Therapeutics (NASDAQ:VIRX) stock increased by 16.8% to $0.68 during Tuesday's pre-market session. Purple Biotech stock rose by 14.48% and Akanda stock rose 12.54% during the same time period. Losers ProKidney ( NASDAQ:PROK) shares decreased by 12.9% in the same session.
Benzinga · 06/11 12:06
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Nauticus Robotics (NASDAQ:KITT) stock is rocketing more than 51% on Tuesday morning. The biggest pre-market stock movers are a share repurchase program, terminated contracts, public offerings and more. Target Hospitality stock is plummeting over 27% on a terminated service agreement.
Investorplace · 06/11 11:40
Weekly Report: what happened at VIRX last week (0603-0607)?
Weekly Report · 06/10 09:25
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Venus Concept (NASDAQ:VERO) stock is rocketing more than 118% alongside heavy pre-market trading. Viracta Therapeutics stock is surging more than 22% on Friday morning. A drug approval, a clinical hold and more are moving stocks this morning.
Investorplace · 06/07 11:22
Weekly Report: what happened at VIRX last week (0527-0531)?
Weekly Report · 06/03 09:26
Weekly Report: what happened at VIRX last week (0520-0524)?
Weekly Report · 05/27 09:26
Viracta Therapeutics Price Target Cut to $11.00/Share From $13.00 by Oppenheimer
Dow Jones · 05/23 12:32
Viracta Therapeutics Is Maintained at Outperform by Oppenheimer
Dow Jones · 05/23 12:32
Oppenheimer Maintains Outperform on Viracta Therapeutics, Lowers Price Target to $11
Benzinga · 05/23 12:22
VIRACTA THERAPEUTICS INC <VIRX.O>: OPPENHEIMER CUTS TARGET PRICE TO $11 FROM $13
Reuters · 05/23 12:17
Oppenheimer Keeps Their Buy Rating on Viracta Therapeutics (VIRX)
TipRanks · 05/23 11:46
U.S. RESEARCH ROUNDUP-Analog Devices, Nvidia, Snowflake
Reuters · 05/23 07:04
Weekly Report: what happened at VIRX last week (0513-0517)?
Weekly Report · 05/20 09:25
Viracta Therapeutics Announces New Employment Inducement Grants
Viracta Therapeutics, Inc. Is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers. The company's Board of Directors granted Michael Faerm stock options to purchase 500,000 shares of common stock. Each option has an exercise price of $.
Barchart · 05/17 15:05
Viracta Therapeutics Welcomes New CFO and Outlines Compensation
TipRanks · 05/14 20:52
Viracta Therapeutics appoints Michael Faerm as CFO
Healthcare Viracta Therapeutics appoints Michael Faerm as CFO. Faerm has more than 25 years of experience in life sciences companies, equity research and investment banking. Viract a Therapeutic appoints Michael faerm as its CFO, effective immediately.
Seeking Alpha · 05/14 11:25
VIRACTA THERAPEUTICS APPOINTS MICHAEL FAERM AS CHIEF FINANCIAL OFFICER
Reuters · 05/14 11:00
Press Release: Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer. Mr. Faerm is a seasoned biotech executive with more than 25 years of experience in life sciences companies. Viracta is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers.
Dow Jones · 05/14 11:00
Weekly Report: what happened at VIRX last week (0506-0510)?
Weekly Report · 05/13 09:26
More
Webull provides a variety of real-time VIRX stock news. You can receive the latest news about Viracta Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About VIRX
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.